Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.28

+0.5%

Nov 5 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1245)	2/19/2002 10:06:22 AM
From: nigel bates	Read Replies (1) of 1475

PDLI lost $250m or so of market cap this morning thanks to this... 9:09AM Protein Design falls 13% pre-market on Cowen Zenepax concerns (PDLI) 20.80: SG Cowen's checks with experts(sic) regarding Zenepax's prospects for maintaining remission in persons with psoriasis indicate that Zenepax has not shown results to suggest the drug is apt to be efficacious. Firm making adjustments to its model to align with PDLI prospects in the years out. Eliminates Zenepax rev in psoriasis until a clearer picture emerges; in 2002 and 2003, reducing rev estimates by $9.8 mln and $95.7 mln, respectively. Additionally, firm is pushing out Xolair related rev to account for development delays. ...strange that BTRN didn't double. <g> nig

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next